BioSpace News Archive

Natalia is an independent journalist based in Brooklyn, New York, who writes about life science, health and technology. She can be reached at natalia.mesa.v@gmail.com.

Pictured: Sign at J&J Vision offices in Silicon Valley

FDA

J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge.

March 21, 2025

·

2 min read

·

Tristan Manalac

Background of scattered on a plain blue background of many tablets in the form of a silhouette of the continents of the world 3d illustration

Manufacturing

J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.

March 21, 2025

·

2 min read

·

Annalee Armstrong

Vector illustration representing kidney care, highlighting the importance of health and medical attention for these vital organs

Rare diseases

Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

March 21, 2025

·

2 min read

·

Dan Samorodnitsky

Pictured: CDC signage at its headquarters in Georg

Vaccines

CDC Vaccine Advisors to Meet in April as Trump Eyes New Agency Director

After withdrawing its nomination for Dave Weldon last week, the Trump administration is now reportedly considering Texas Republican Michael Burgess to head the Centers for Disease Control and Prevention.

March 21, 2025

·

2 min read

·

Tristan Manalac

Man making decision what path, direction to take. Arrows pointing in different directions

Business

Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.

March 21, 2025

·

2 min read

·

Tristan Manalac

Press Releases

TiumBio’s Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development

March 21, 2025

·

3 min read

Press Releases

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025